Deng Shengxing, co-founder and CEO of Ruisheng Securities The main business of WuXi Biologics (2269) is to provide biological agent discovery, development and production services, with the development direction of the CDMO model of customized R&D and production of pharmaceutical contracts, providing pharmaceutical R&D, and production outsourcing services, which will help promote the
...more